Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab

Translational Andrology and Urology

Volumn 1, Issue 2, 2012, Pages 118-119

  Wolff, Johannes M ^a   Schmid, Hans Peter ^b  

^a Frauenklinik AKH Viersen   (Germany)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875439754     PISSN: 22234683     EISSN: 22234691     Source Type: Journal    
DOI: 10.3978/j.issn.2223-4683.2012.05.03     Document Type: Article

References (1)

1. Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46.